The Outcome of Hodgkin Lymphoma With Reference to Prognostic Markers.

Ahmed, Rehana; Tariq, Faryal; Ashfaq, Javeria; Thakur, Warkha; Zafar, Sidra; Danish, Asma; Borhany, Munira

Ahmed, Rehana; Tariq, Faryal; Ashfaq, Javeria; Thakur, Warkha; Zafar, Sidra; Danish, Asma; Borhany, Munira.

Afiliação

Ahmed R; Clinical Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
Tariq F; Clinical Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
Ashfaq J; Internal Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.
Thakur W; Clinical Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
Zafar S; Research and Development, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
Danish A; Clinical Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
Borhany M; Clinical Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.

Cureus ; 14(8): e28421, 2022 Aug.

Article em En | MEDLINE | ID: mdl-36176827

Palavras-chave

chemotherapy; erythrocyte sedimentation rate; hodgkin's lymphoma; prognostic biomarkers; radiotherapy (rt)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cureus Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google